What is Alivation Research?
Founded in 1998 by Dr. Walt Duffy, Alivation Research has evolved from a specialized psychiatric practice into a comprehensive, multi-disciplinary healthcare ecosystem. Based in Lincoln, Nebraska, the company operates through several key affiliates, including Alivation Health, Alivation Pharmacy, and Alivation Research. This integrated approach allows the organization to provide a seamless clinical experience, addressing both behavioral health and primary care needs in a single, technology-enabled environment.
The company's market position is defined by its commitment to innovation and its ability to synthesize complex medical services into a cohesive patient journey. By incorporating on-site pharmacy capabilities and advanced research initiatives, Alivation differentiates itself from traditional clinical providers. This operational synergy not only improves patient outcomes but also creates a scalable framework for future growth in the competitive healthcare services market.
How much funding has Alivation Research raised?
Alivation Research has raised a total of $407K across 2 funding rounds:
Debt
$350K
Debt
$57K
Debt (2020): $350K with participation from PPP
Debt (2021): $57K led by PPP
Key Investors in Alivation Research
PPP
Public-Private Partnership
Undisclosed Investor
An institutional partner participating in the funding round to facilitate the growth of integrated clinical and research services.
Undisclosed Investor
A strategic backer focused on the long-term development of behavioral health and medical research infrastructure.
What's next for Alivation Research?
With the recent influx of capital, Alivation Research is poised to accelerate its strategic roadmap, focusing on the expansion of its clinical footprint and the enhancement of its proprietary healthcare technology stack. The company is expected to prioritize the scaling of its research division, leveraging its existing patient data and clinical expertise to participate in high-value medical trials and therapeutic development.
Furthermore, the organization will likely focus on optimizing its integrated service delivery model to improve operational efficiency across its pharmacy and family practice units. As the company continues to navigate the complexities of the modern healthcare environment, this latest round of financing provides the stability required to pursue long-term growth objectives, potentially including geographic expansion or the acquisition of complementary clinical assets to further solidify its leadership in integrated care.
